Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study Assessed the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.

Phase 2

Completed

Conditions: Aplastic Anemia

Interventions: Drug: Eltrombopag

First Posted Date: 2019-06-17

Last Posted Date: 2025-02-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT03988608

Locations: 🇨🇳
Novartis Investigative Site, Tianjin, China

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Phase 3

Completed

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)

Interventions: Drug: valsartan
Drug: sacubitril/valsartan
Drug: valsartan matching placebo
Drug: sacubitril/valsartan matching placebo

First Posted Date: 2019-06-17

Last Posted Date: 2025-03-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 467

Registration Number: NCT03988634

Locations: 🇺🇸
Boston Univeristy Medical Center ., Boston, Massachusetts, United States
🇺🇸
Colorado Heart and Vascular ., Lakewood, Colorado, United States
🇺🇸
Swedish Medical Ctr Cardiovascular Re, Seattle, Washington, United States

and more 83 locations

A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients

Phase 4

Completed

Conditions: Migraine Disorders

Interventions: Drug: placebo
Drug: erenumab

First Posted Date: 2019-06-06

Last Posted Date: 2021-08-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT03977649

Locations: 🇮🇹
Novartis Investigative Site, Napoli, Italy

Pediatric Long-Term Follow-up and Rollover Study

Phase 4

Active, not recruiting

Conditions: Diffuse Astrocytoma
Anaplastic Astrocytoma
Astrocytoma
Oligodendroglioma, Childhood
Anaplastic Oligodendroglioma
Glioblastoma
Pilocytic Astrocytoma
Giant Cell Astrocytoma
Pleomorphic Xanthoastrocytoma
Anaplastic Pleomorphic Xanthoastrocytoma

Interventions: Drug: dabrafenib
Drug: trametinib

First Posted Date: 2019-06-05

Last Posted Date: 2025-06-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 163

Registration Number: NCT03975829

Locations: 🇺🇸
Childrens National Hospital, Washington, District of Columbia, United States
🇺🇸
Phoenix Children s Hospital, Phoenix, Arizona, United States
🇺🇸
Nicklaus Childrens Hospital, Miami, Florida, United States

and more 9 locations

This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Canakinumab
Drug: Pembrolizumab

First Posted Date: 2019-05-30

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 88

Registration Number: NCT03968419

Locations: 🇺🇸
University of Kansas Medical Center Neurology Dept., Kansas City, Kansas, United States
🇺🇸
Methodist Hospital / Methodist Cancer Center, Houston, Texas, United States
🇺🇸
UCLA Oncology Hematology, La Jolla, California, United States

and more 2 locations

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Phase 1

Active, not recruiting

Conditions: Diffuse Large B-cell Lymphoma
Large B-cell Lymphoma
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Biological: Rapcabtagene autoleucel single agent
Drug: Ibrutinib

First Posted Date: 2019-05-23

Last Posted Date: 2025-06-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 206

Registration Number: NCT03960840

Locations: 🇺🇸
University of California LA, Los Angeles, California, United States
🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

and more 13 locations

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Phase 3

Recruiting

Conditions: C3 Glomerulopathy
Immune-complex-membranoproliferative Glomerulonephritis

Interventions: Drug: LNP023

First Posted Date: 2019-05-20

Last Posted Date: 2025-05-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 225

Registration Number: NCT03955445

Locations: 🇺🇸
Georgia Nephrology Research Inst, Lawrenceville, Georgia, United States
🇺🇸
University of Iowa Health Care, Iowa City, Iowa, United States
🇺🇸
Col Uni Med Center New York Presby, New York, New York, United States

and more 1 locations

Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD

Phase 3

Completed

Conditions: Age-Related Macular Degeneration
Wet Macular Degeneration
Macular Degeneration
Retinal Diseases
Eye Diseases
Retinal Degeneration

Interventions: Biological: brolucuzumab 6 mg IVT

First Posted Date: 2019-05-17

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT03954626

Locations: 🇵🇷
Novartis Investigative Site, Arecibo, Puerto Rico

A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients

Phase 2

Terminated

Conditions: Atopic Dermatitis

Interventions: Drug: ZPL389 30mg
Drug: ZPL389 50mg
Drug: TCS and/or TCI

First Posted Date: 2019-05-13

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 123

Registration Number: NCT03948334

Locations: 🇬🇧
Novartis Investigative Site, Portsmouth, United Kingdom

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

Phase 2

Terminated

Conditions: Myelodysplastic Syndromes

Interventions: Drug: MBG453
Drug: Placebo
Drug: Hypomethylating agents

First Posted Date: 2019-05-13

Last Posted Date: 2025-04-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 127

Registration Number: NCT03946670

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Mary Crowley Cancer Research, Dallas, Texas, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy